Inmunoterapia en diabetes mellitus tipo 1. ¿Quo vadis?

Polychronakos, 2011, Understanding type 1 diabetes through genetics: Advances and prospects, Nat Rev Genet, 12, 781, 10.1038/nrg3069 Beyan, 2012, Guts, germs, and meals: The origin of type 1 diabetes, Curr Diab Rep, 12, 456, 10.1007/s11892-012-0298-z Patterson, 2009, Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study, Lancet, 373, 2027, 10.1016/S0140-6736(09)60568-7 Geenen, 2012, Presentation of neuroendocrine self in the thymus: A necessity for integrated evolution of the immune and neuroendocrine systems, Ann N Y Acad Sci, 1261, 42, 10.1111/j.1749-6632.2012.06624.x Marino, 2012, B cells as effectors and regulators of autoimmunity, Autoimmunity, 45, 377, 10.3109/08916934.2012.665527 Diana, 2013, Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes, Nat Med, 19, 65, 10.1038/nm.3042 Yang, 2006, Lessons on autoimmune diabetes from animal models, Clin Sci (Lond), 110, 627, 10.1042/CS20050330 Roep, 2004, Satisfaction (not) guaranteed: Re-evaluating the use of animal models of type 1 diabetes, Nat Rev Immunol, 4, 989, 10.1038/nri1502 Palmer, 2009, C-peptide in the natural history of type 1 diabetes, Diabetes Metab Res Rev, 25, 325, 10.1002/dmrr.943 Achenbach, 2005, Natural history of type 1 diabetes, Diabetes, 54, S25, 10.2337/diabetes.54.suppl_2.S25 Feutren, 1986, Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial, Lancet, 2, 119, 10.1016/S0140-6736(86)91943-4 Parving, 1999, Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study, Diabetes Care, 22, 478, 10.2337/diacare.22.3.478 Silverstein, 1988, Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus, N Engl J Med, 319, 599, 10.1056/NEJM198809083191002 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 1998, Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group, Ann Intern Med, 128, 517, 10.7326/0003-4819-128-7-199804010-00001 Palmer, 2004, C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21-22 October 2001, Diabetes, 53, 250, 10.2337/diabetes.53.1.250 Gandhi, 2008, Immunotherapeutic agents in type 1 diabetes: A systematic review and meta-analysis of randomized trials, Clin Endocrinol (Oxf), 69, 244, 10.1111/j.1365-2265.2008.03179.x Herold, 2002, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N Engl J Med, 346, 1692, 10.1056/NEJMoa012864 Keymeulen, 2005, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes, N Engl J Med, 352, 2598, 10.1056/NEJMoa043980 Ludvigsson, 2008, GAD treatment and insulin secretion in recent-onset type 1 diabetes, N Engl J Med, 359, 1909, 10.1056/NEJMoa0804328 2002, Effects of insulin in relatives of patients with type 1 diabetes mellitus, N Engl J Med, 346, 1685, 10.1056/NEJMoa012350 Skyler, 2005, Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1, Diabetes Care, 28, 1068, 10.2337/diacare.28.5.1068 Levy, 1999, The stiff-person syndrome: An autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid, Ann Intern Med, 131, 522, 10.7326/0003-4819-131-7-199910050-00008 Ludvigsson, 2012, GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus, N Engl J Med, 366, 433, 10.1056/NEJMoa1107096 Peakman, 2010, Antigen-specific immunotherapy for type 1 diabetes: Maximizing the potential, Diabetes, 59, 2087, 10.2337/db10-0630 Chatenoud, 2003, CD3-specific antibody-induced active tolerance: from bench to bedside, Nat Rev Immunol, 3, 123, 10.1038/nri1000 Herold, 2013, Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomised controlled trial, Diabetologia, 56, 391, 10.1007/s00125-012-2753-4 Sherry, 2011, Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial, Lancet, 378, 487, 10.1016/S0140-6736(11)60931-8 Cernea, 2009, Challenges in developing endpoints for type 1 diabetes intervention studies, Diabetes Metab Res Rev, 25, 694, 10.1002/dmrr.1002 Onrust, 1999, Rituximab, Drugs, 58, 79, 10.2165/00003495-199958010-00009 Pescovitz, 2009, Rituximab B-lymphocyte depletion, and preservation of beta-cell function, N Engl J Med, 361, 2143, 10.1056/NEJMoa0904452 Vincenti, 2007, T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and transplantation, Annu Rev Med, 58, 347, 10.1146/annurev.med.58.080205.154004 Orban, 2011, Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial, Lancet, 378, 412, 10.1016/S0140-6736(11)60886-6 Dinarello, 2012, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases, Nat Rev Drug Discov, 11, 633, 10.1038/nrd3800 Moran, 2013, Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials, Lancet, 10.1016/S0140-6736(13)60023-9 Gottlieb, 2010, Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes, Diabetes Care, 33, 826, 10.2337/dc09-1349 Long, 2012, Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function, Diabetes, 61, 2340, 10.2337/db12-0049 Staeva, 2013, Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials, Diabetes, 62, 9, 10.2337/db12-0562 Lernmark, 2013, Immune therapy in type 1 diabetes mellitus, Nat Rev Endocrinol, 9, 92, 10.1038/nrendo.2012.237